

ALL IMAGES VIDEOS

5,820 Results

Any time ▾

[Treatment of uncommon EGFR mutations in non-small cell ...](#)<https://tlcr.amegroups.com/article/view/28832/21558> ▾

Nazartinib, a covalent EGFR inhibitor similar to osimertinib, has also exhibited potential benefits for exon 20 insertions in preclinical studies (70). A clinical trial of this drug is ongoing in NSCLC patients with common EGFR mutations, but effects in patients with exon 20 insertions have not been observed.

Cited by: 20

Author: Tianli Zhang, Bing Wan, Yuan Zhao, Chul...

Publish Year: 2019

[Afatinib for the Treatment of NSCLC Harboring Uncommon ...](#)[https://www.jto.org/article/S1556-0864\(20\)30014-9/fulltext](https://www.jto.org/article/S1556-0864(20)30014-9/fulltext)

Jan 10, 2020 • Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors



See more

Long-Term Survival of Over 6 Years with Afatinib ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149342>

Apr 16, 2021 · **Lung cancer** is the leading cause of **cancer**-related death worldwide [], with **non-small cell lung cancer** (NSCLC) accounting for approximately 85% of all cases [], and **lung** adenocarcinoma and squamous cell carcinoma representing the most common NSCLC subtypes []. An increased understanding of the genomic landscape in NSCLC has led to the identification of targetable ...

Author: Hai-Yan Tu, Yang-Si Li, Jin-Ji Yang, Hu... Publish Year: 2021

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa2027071>

Sep 19, 2020 · **Osimertinib** is standard-of-care therapy for previously untreated **epidermal growth factor receptor (EGFR)** mutation-positive advanced **non-small-cell lung cancer** ...

Cited by: 107

Author: Yi-Long Wu, Masahiro Tsuboi, Jie He, Tho...

Publish Year: 2020

PEOPLE ALSO ASK

Are there any EGFR mutations in lung cancer?



Which is better for NSCLC patients afatinib or gefitinib?



Are there any EGFR mutations that are resistant to gefitinib?



Are there any EGFR TKIs for NSCLC?




Feedback

Choroidal metastasis from non-small-cell lung cancer ...

27-Jun-2021 05:42PM

1579 words • 5 matches • 5 sources

FAQ

 iThenticate

67500_Auto_Edited - check2.docx

Quotient Excluded
Bibliography Included

7%
(1000000)

4

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 67500

Manuscript Type: CASE REPORT

Non-small-cell lung cancer with *EGFR* L861Q-L833F benefits from both afatinib and osimertinib: A case report

Zhang Y *et al.* Treatments for NSCLC with L861Q-L833F

Yao Zhang, Ji-Qiao Shen, Lin Shao, Yan Chen, Lei Lei, Jia-lei Wang

Match Overview

1

Internet 26 words
crawled on 17-Jan-2021
[doaj.org](#)

2%

2

Internet 21 words
crawled on 25-May-2021
[www.science.gov](#)

1%

3

Crossref 16 words
Yakun Li, Rui Zhang, Yongzhao Zhou, Juan Song, Wensin Luo,
Panwen Tian, Weimin Li. "Combined Use of Crizotinib and Gef

1%

4

Internet 14 words
crawled on 15-Feb-2020
[itpublishing.blob.core.windows.net](#)

1%

5

Internet 13 words
crawled on 20-Mar-2021
[bmcbiotechnol.biomedcentral.com](#)

1%

国内版

国际版

Non-small-cell lung cancer with epidermal growth factor receptor L



ALL

IMAGES

VIDEOS

7,020 Results

Any time ▾

[Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung ...](#)

<https://www.nejm.org/doi/full/10.1056/NEJMoa2027071>

Sep 19, 2020 · Osimertinib is standard-of-care therapy for previously untreated **epidermal growth factor receptor** (EGFR) mutation-positive advanced **non-small-cell lung cancer** (NSCLC). The efficacy and safety ...

Cited by: 107

Author: Yi-Long Wu, Masahiro Tsuboi, Jie He, Th...

Publish Year: 2020

EXPLORE FURTHER

Phase III **ADAURA Trial: Practice Changing Results for ...**

[www.physiciansweekly.com](#)

ADAURA: Phase III, Double-blind, Randomized Study of ...

[pubmed.ncbi.nlm.nih.gov](#)

Adjuvant **Osimertinib** Succeeds in Phase III **ADAURA Trial** in ...

[www.onclive.com](#)

Osimertinib Mesylate - National Cancer Institute

[www.cancer.gov](#)

No Benefit for Post-operative Radiotherapy in **Non-small ...**

[www.esmo.org](#)

Recommended to you based on what's popular • Feedback

[Rare epidermal growth factor receptor \(EGFR\) mutations in ...](#)

<https://www.sciencedirect.com/science/article/pii/S1044579X19303025>

Apr 01, 2020 · Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in **non-small cell lung cancer** (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation) comprise the vast majority of EGFR mutations and are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi).

Cited by: 31

Author: Peter T. Harrison, Simon Vyse, Paul H. H...

Publish Year: 2020

[Treatment of uncommon EGFR mutations in non-small cell ...](#)

<https://tcr.amegroups.com/article/view/28832/21558> ▾

Introduction. **Non-small cell lung cancer** (NSCLC) accounts for approximately 85% of **lung cancer** cases and has high mortality worldwide (1,2). In China, it is also the most common **cancer** and leading cause of **cancer-related deaths** (). Targeted therapy has led to a new era in the treatment of NSCLC with the development of detection techniques for **epidermal growth factor receptor** (EGFR) mutations.

Cited by: 24

Author: Tianli Zhang, Bing Wan, Yuan Zhao, Chuli...

Publish Year: 2020